NDAORALTABLET
Approved
Jun 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
METHYLDOPA (methyldopa) by Molecular Devices is clinical pharmacology methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. First approved in 1984.
Drug data last refreshed 55m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Methyldopa is an oral antihypertensive small molecule that works by inhibiting aromatic-amino-acid decarboxylase and metabolizing to alpha-methylnorepinephrine, which lowers blood pressure through central alpha-adrenergic receptor stimulation and reduction of plasma renin activity. It is used as a first-line or adjunctive treatment for hypertension. The drug maintains cardiac output without acceleration and produces effective supine blood pressure reduction with minimal postural hypotension.
LOE Approaching
Approaching loss of exclusivity signals team consolidation; focus shifts to generic transition planning and retained institutional presence in cardiology.
Mechanism of Action
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then…
Worked on METHYLDOPA at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.